Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis

Y. Morita, Hirofumi Makino, K. Ota, Jun Wada, Kenichi Shikata, N. Kashihara, S. Ikeda, T. Ogura, Z. Ota

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Effect of heparin and low-molecular-weight heparin (LMWH) were evaluated on 15 patients with proliferative glomerulonephritis with various degrees of sclerosing legion. Five cases were subcutaneously administered with 7000 to 11000 units of heparin for 4 weeks. Ten cases were administered with 60 unit/kg of LMWH by drip infusion for 4 weeks. Eleven cases were treated with prednisolone and all cases were treated with anti-platelet agent as well. Urinary protein excretion reduced from 3.0 ± 1.8 to 1.8 ± 0.6 g/day in the heparin-treated group and from 2.4 ± 1.9 to 1.8 ± 1.4 g/day in the LMWH-treated group, respectively. There were no remarkable changes in the renal functions of both groups. In one case, both heparin and LMWH brought about reduction of proteinuria. Therefore, LMWH reduced urinary protein excretion by the same mechanism as heparin. The LMWH has an advantage over heparin in that the former has less risk of causing bleeding. We conclude that heparin and LMWH reduce proteinuria in some patients with proliferative glomerulonephritis. The LMWH is beneficial in the treatment of proliferative glomerulonephritis with a sclerosing lesion.

Original languageEnglish
Pages (from-to)832-838
Number of pages7
JournalNippon Jinzo Gakkai shi
Volume36
Issue number7
Publication statusPublished - 1994

Fingerprint

Low Molecular Weight Heparin
Glomerulonephritis
Heparin
Proteinuria
Prednisolone
Intravenous Infusions
Proteins
Blood Platelets
Hemorrhage
Kidney

Keywords

  • heparin
  • low-molecular-weight heparin
  • proliferative glomerulonephritis
  • treatment

ASJC Scopus subject areas

  • Nephrology

Cite this

Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis. / Morita, Y.; Makino, Hirofumi; Ota, K.; Wada, Jun; Shikata, Kenichi; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z.

In: Nippon Jinzo Gakkai shi, Vol. 36, No. 7, 1994, p. 832-838.

Research output: Contribution to journalArticle

Morita, Y, Makino, H, Ota, K, Wada, J, Shikata, K, Kashihara, N, Ikeda, S, Ogura, T & Ota, Z 1994, 'Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis', Nippon Jinzo Gakkai shi, vol. 36, no. 7, pp. 832-838.
Morita, Y. ; Makino, Hirofumi ; Ota, K. ; Wada, Jun ; Shikata, Kenichi ; Kashihara, N. ; Ikeda, S. ; Ogura, T. ; Ota, Z. / Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis. In: Nippon Jinzo Gakkai shi. 1994 ; Vol. 36, No. 7. pp. 832-838.
@article{8a25b62b282b4a37816fdb5f6705e4c8,
title = "Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis",
abstract = "Effect of heparin and low-molecular-weight heparin (LMWH) were evaluated on 15 patients with proliferative glomerulonephritis with various degrees of sclerosing legion. Five cases were subcutaneously administered with 7000 to 11000 units of heparin for 4 weeks. Ten cases were administered with 60 unit/kg of LMWH by drip infusion for 4 weeks. Eleven cases were treated with prednisolone and all cases were treated with anti-platelet agent as well. Urinary protein excretion reduced from 3.0 ± 1.8 to 1.8 ± 0.6 g/day in the heparin-treated group and from 2.4 ± 1.9 to 1.8 ± 1.4 g/day in the LMWH-treated group, respectively. There were no remarkable changes in the renal functions of both groups. In one case, both heparin and LMWH brought about reduction of proteinuria. Therefore, LMWH reduced urinary protein excretion by the same mechanism as heparin. The LMWH has an advantage over heparin in that the former has less risk of causing bleeding. We conclude that heparin and LMWH reduce proteinuria in some patients with proliferative glomerulonephritis. The LMWH is beneficial in the treatment of proliferative glomerulonephritis with a sclerosing lesion.",
keywords = "heparin, low-molecular-weight heparin, proliferative glomerulonephritis, treatment",
author = "Y. Morita and Hirofumi Makino and K. Ota and Jun Wada and Kenichi Shikata and N. Kashihara and S. Ikeda and T. Ogura and Z. Ota",
year = "1994",
language = "English",
volume = "36",
pages = "832--838",
journal = "Japanese Journal of Nephrology",
issn = "0385-2385",
publisher = "Japanese Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis

AU - Morita, Y.

AU - Makino, Hirofumi

AU - Ota, K.

AU - Wada, Jun

AU - Shikata, Kenichi

AU - Kashihara, N.

AU - Ikeda, S.

AU - Ogura, T.

AU - Ota, Z.

PY - 1994

Y1 - 1994

N2 - Effect of heparin and low-molecular-weight heparin (LMWH) were evaluated on 15 patients with proliferative glomerulonephritis with various degrees of sclerosing legion. Five cases were subcutaneously administered with 7000 to 11000 units of heparin for 4 weeks. Ten cases were administered with 60 unit/kg of LMWH by drip infusion for 4 weeks. Eleven cases were treated with prednisolone and all cases were treated with anti-platelet agent as well. Urinary protein excretion reduced from 3.0 ± 1.8 to 1.8 ± 0.6 g/day in the heparin-treated group and from 2.4 ± 1.9 to 1.8 ± 1.4 g/day in the LMWH-treated group, respectively. There were no remarkable changes in the renal functions of both groups. In one case, both heparin and LMWH brought about reduction of proteinuria. Therefore, LMWH reduced urinary protein excretion by the same mechanism as heparin. The LMWH has an advantage over heparin in that the former has less risk of causing bleeding. We conclude that heparin and LMWH reduce proteinuria in some patients with proliferative glomerulonephritis. The LMWH is beneficial in the treatment of proliferative glomerulonephritis with a sclerosing lesion.

AB - Effect of heparin and low-molecular-weight heparin (LMWH) were evaluated on 15 patients with proliferative glomerulonephritis with various degrees of sclerosing legion. Five cases were subcutaneously administered with 7000 to 11000 units of heparin for 4 weeks. Ten cases were administered with 60 unit/kg of LMWH by drip infusion for 4 weeks. Eleven cases were treated with prednisolone and all cases were treated with anti-platelet agent as well. Urinary protein excretion reduced from 3.0 ± 1.8 to 1.8 ± 0.6 g/day in the heparin-treated group and from 2.4 ± 1.9 to 1.8 ± 1.4 g/day in the LMWH-treated group, respectively. There were no remarkable changes in the renal functions of both groups. In one case, both heparin and LMWH brought about reduction of proteinuria. Therefore, LMWH reduced urinary protein excretion by the same mechanism as heparin. The LMWH has an advantage over heparin in that the former has less risk of causing bleeding. We conclude that heparin and LMWH reduce proteinuria in some patients with proliferative glomerulonephritis. The LMWH is beneficial in the treatment of proliferative glomerulonephritis with a sclerosing lesion.

KW - heparin

KW - low-molecular-weight heparin

KW - proliferative glomerulonephritis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0027991260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027991260&partnerID=8YFLogxK

M3 - Article

C2 - 8072221

AN - SCOPUS:0027991260

VL - 36

SP - 832

EP - 838

JO - Japanese Journal of Nephrology

JF - Japanese Journal of Nephrology

SN - 0385-2385

IS - 7

ER -